DBV TECHNOLOGIES SPON ADS EACH REPR 5 ORD SHS (R/S)
DBV Technologies S.A. (DBVT) is a clinical-stage biotechnology company developing epicutaneous immunotherapy delivered via a skin patch, primarily aimed at treating food allergies. Investors should know DBV focuses on a differentiated delivery platform and a pipeline centred on desensitising allergic patients without systemic exposure typical of oral therapies. The company has undergone periods of regulatory scrutiny and variable clinical outcomes, which are common in biotech development and can affect the share price. With a market capitalisation of approximately $478.85M, DBV remains a speculative investment suited to those comfortable with clinical‑stage risk, binary trial readouts and long timelines to commercialisation. Financial results, trial updates and regulatory decisions are key value drivers. This information is educational only and not personalised investment advice; values can rise or fall and past performance does not guarantee future returns.
Stock Performance Snapshot
Financial Health
DBV Technologies is generating modest revenue and cash flow, highlighting some stability in operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
AbbVie
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
ASTRAZENECA PLC
AstraZeneca is a global biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing innovative medicines.
AMGEN INC
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Baskets Featuring DBVT
The Post-Pandemic Pediatric Pivot
The FDA's potential withdrawal of Pfizer's COVID vaccine for young children is reshaping the pediatric pharmaceutical landscape. This regulatory shift could create a significant market opening for other drugmakers focused on pediatric vaccines and therapies.
Published: August 13, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage pipeline
DBV’s patch approach targets a clear clinical need in food allergy treatment; clinical results will be a major driver, though trial outcomes can be binary.
Regulatory sensitivity
Regulatory feedback and approvals are pivotal; positive decisions can boost prospects while setbacks can weigh heavily on valuation.
Allergy market potential
Food allergies are a growing public‑health concern, which may offer long‑term opportunity, but commercial success is not guaranteed and depends on adoption.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
